Company

Overview

iCo Therapeutics Inc. (ICO: TSX-V, ICOTF:OTCQX) is a biotechnology company. By focusing efforts on development instead of research, iCo's business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization and develop them by redosing or reformulating them for new or expanded labels. Management strength is supported by an impressive group of Directors and Advisors.

There is a significant decrease in development risk associated with targeting existing drugs, including:

  • Reduced risk of adverse events since clinical testing and systemic use in humans has already been established.
  • Scale-up and manufacturing issues have already been addressed since clinical grade material has been made.
  • The target and mechanism of action has been identified.

 

Copyright 2010 ICO Therapeutics | Disclaimer